Literature DB >> 12612321

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome.

G R V Hughes1.   

Abstract

The antiphospholipid syndrome (APS, Hughes' syndrome), first described in 1983, is a prothrombotic disease in which neurological events feature prominently. Strokes, transient ischaemic attacks, and headaches (including migraine) are important complications. However, it is clear that other neurological symptoms, including diplopia, memory loss, ataxia, and "multiple sclerosis-like" features are common. A notable feature of Hughes' syndrome is the clinical response to anticoagulants; features such as headache and memory loss often improving dramatically with appropriate warfarin dosage. APS may well become recognised as an important (and potentially treatable) cause of neurological disease.

Entities:  

Mesh:

Year:  2003        PMID: 12612321      PMCID: PMC1742609          DOI: 10.1136/pmj.79.928.81

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  11 in total

1.  Migraine and stroke in young women.

Authors:  M J Cuadrado; M A Khamashta; G R Hughes
Journal:  QJM       Date:  2000-05

2.  Migraine in Hughes syndrome--heparin as a therapeutic trial?

Authors:  M J Cuadrado; M A Khamashta; D D'Cruz; G R Hughes
Journal:  QJM       Date:  2001-02

Review 3.  Sticky blood and headache.

Authors:  M J Cuadrado; M A Khamashta; G R Hughes
Journal:  Lupus       Date:  2001       Impact factor: 2.911

4.  Epilepsy: an early symptom of systemic lupus erythematosus.

Authors:  C G Mackworth-Young; G R Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

5.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

6.  Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders.

Authors:  J T Peltola; A Haapala; J I Isojärvi; A Auvinen; J Palmio; K Latvala; P Kulmala; S Laine; O Vaarala; T Keränen
Journal:  Am J Med       Date:  2000-12-15       Impact factor: 4.965

Review 7.  Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.

Authors:  M J Cuadrado; M A Khamashta; A Ballesteros; T Godfrey; M J Simon; G R Hughes
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

8.  The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.

Authors:  M L Bertolaccini; T Atsumi; A Escudero Contreras; M A Khamashta; G R Hughes
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

9.  Cerebral infarction in systemic lupus: association with anticardiolipin antibodies.

Authors:  E N Harris; A E Gharavi; R A Asherson; M L Boey; G R Hughes
Journal:  Clin Exp Rheumatol       Date:  1984 Jan-Mar       Impact factor: 4.473

10.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

View more
  19 in total

1.  Acrylamine-induced autoimmune phenomena.

Authors:  Bruce Rothschild
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

2.  Hughes syndrome (the antiphospholipid syndrome): a disease of our time.

Authors:  Graham R V Hughes
Journal:  Inflammopharmacology       Date:  2010-12-05       Impact factor: 4.473

Review 3.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

4.  Antiphospholipid syndrome: A disease of protean face.

Authors:  Mohammadreza Ardalan; Amir Vahedi
Journal:  J Nephropathol       Date:  2013-01-01

5.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 6.  Demyelination in rheumatic diseases.

Authors:  A Theodoridou; L Settas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

7.  Mania: psychiatric manifestations of the antiphospholipid syndrome.

Authors:  Haniya Raza; Steven A Epstein; Maryland Pao; Donald L Rosenstein
Journal:  Psychosomatics       Date:  2008 Sep-Oct       Impact factor: 2.386

Review 8.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

Review 9.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 10.  Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.

Authors:  Miguel Leal Rato; Matilde Bandeira; Vasco C Romão; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-14       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.